How much funding has Magellan Life Sciences raised?

Magellan Life Sciences has raised $225K in total funding, most recently a Seed round.

Who are Magellan Life Sciences's investors?

Magellan Life Sciences's investors include SOSV.

When was Magellan Life Sciences founded?

Magellan Life Sciences was founded in 2013.

Where is Magellan Life Sciences headquartered?

Magellan Life Sciences is headquartered in United Kingdom.

What industry is Magellan Life Sciences in?

Magellan Life Sciences operates in Biotech, Climate Tech.

How many employees does Magellan Life Sciences have?

Magellan Life Sciences has 1-10 employees.

Magellan Life Sciences

Discovering, deciphering, and developing unique plant proteins

United Kingdom · Founded 2013 · $225K raised

Biotech

Climate Tech

Employees: 1–10
Founded: 2013
Business Model: B2B
Website: magellanlifesciences.com

Total Funding: $225K
Last Round: $225K SeedNov 2017
Rounds: 1

About

Magellan Life Sciences is a synthetic biology company that uses its proprietary X-Seed® Precision Respiration™ platform to engineer and commercialize complex plant proteins at industrial scale. Their lead program focuses on Brazzein, a rare natural protein sweetener derived from West African fruit, as a sustainable alternative to sugar and high-fructose corn syrup. The company's platform offers higher yields and simplified downstream purification compared to conventional bioprocessing, targeting the food security and alternative sweetener markets. MLS was part of SOSV's IndieBio 2018 cohort, received Innovate UK grants, and received interest from Roquette Ventures.

Summary

Magellan Life Sciences is a Biotech company based in United Kingdom, founded in 2013. It has raised $225K in total across 1 round, most recently a $225K Seed round in Nov 2017. Investors include SOSV.